cabazitaxel

Name: Pharmaffiliates
Address: Plot Number 225 ,Industrial Area, Phase II, Panchkula, 134109, IN
Telephone: +91-172-5066494
Price range: $650-$950

Cabazitaxel was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a semi-synthetic derivative of a natural taxoid. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.. Reference standards of Cabazitaxel API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below

stdClass Object
(
    [pname] => De-boc Cabazitaxel
    [catalogue_number] => PA 03 01510
    [category_ids] => ,170,82,81,80,78,75,71,70,69,
    [chemical_name] => 
    [weight] => 735.82
    [form] => C40H49NO12
    [cas] => 1638286-64-2
    [pslug] => 1638286-64-2-de-boc-cabazitaxel-pa0301510
    [latest_product] => 0
    [linkproducts] => 1
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)